Kasim Kutay, CEO of Novo Holdings, leads a world-leading life sciences investor that deploys capital across all. See sector focus and contact routes.
Kasim Kutay, CEO of Novo Holdings, leads a world-leading life sciences investor that deploys capital across all development stages—from seeds to principal investments—primarily in biotech, pharma, and bioindustrial sectors, with a distinctive thesis centered on planetary health and green technology including decarbonization. The firm’s venture unit deployed $530 million in 2023, adding 18 investments such as 4D Molecular, Alentis Therapeutics, and Terremoto Biosciences to its portfolio. Kutay describes Novo Holdings as a financially driven venture investor without strategic interests, aiming to maximize returns for its owner, the Novo Nordisk Foundation, while allocating approximately $35 billion by 2030, with $5–7 billion annually targeted for life sciences.
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in Hellerup.
Investors like Kasim Kutay · Full investor directory · Investor access · Company funding database